Epirubicin治疗曾化疗与未化疗晚期乳腺癌的疗效对比

Treatment of Advanced Breast Cancer with Epirubicin:Comparison of Previously Untreated Patients with Treated

Epirubicin单药治疗晚期乳腺癌,按照用过化疗与未用过化疗的病人分为两组。两组病人均按每次剂量递增的方法,50mg/M^2,60mg/M^2,70mg/M^2～80mg/M^2静脉注射,每3周1次。结果,未曾化疗的病人达PR的4/9例(44.4％),MR3/9(33.3％),NC2/9(22％)。曾用化疗的病人达CR1/11例(9％),MR2/11例(18％),NC1例,PD7例。Epi-Dx的心肌毒性与骨髓毒性较低,无1例发生急性充血性心力衰竭。本实验表明未曾化疗的病人比曾经化疗的病人疗效较高。

Twenty patients with advanced breast cancer were treated with Epirubicin which was started with 50 mg/m^2 escalating to 60 mg/m^2, 70 mg/m^2, until 80 mg/m^2 was reached. The response in 11 patients who previously had been treated with chemothera- py showed CR in 1, MR in 2, NC in 1 and PD in 7 with an overall response rate 9%. 9 patients who had not received any prior chemotherapy PR was observed in 4, MR in 3, NC in 2. A response rate of 44.4% was achieved. The cardiac toxicity and myelosuppressive effect of Epirubisin were very mild, and congestive heart failure did not occur. The authors conclude that patients who had no previous chemotherapy responded much better than those who had.